Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-ARC002 in Advanced Solid Tumors
NCT07763652Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-ARC002 in solid tumor, Esophageal Squamous Cell Carcinoma (ESCC), gastric cancer (GC) and 1 more, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 42 days, Maximum Tolerated Dose at 42 days and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
BL-ARC002
03
Conditions
solid tumorEsophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07763652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07763652.